ALK appoints SVP of R&D for North America and International Markets
Copenhagen, 2017-03-03 09:48 CET (GLOBE NEWSWIRE) --
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced the appointment of Hendrik Nolte, M.D., Med.Sc.D, as Senior Vice President of Research and Development for North America and International Markets, based in the USA.
Hendrik Nolte will be responsible for ALK’s R&D strategy in North America and International markets including China, and will work in collaboration with ALK’s partners for Russia, Japan, South-East Asia, Australia and New Zealand.
Henrik Jacobi, ALK’s Executive Vice President of Research and Development, said: “Hendrik’s reputation in the allergy immunotherapy field is unsurpassed and we welcome him to ALK as a key figure in the scale-up of our North American operations and an important contributor to our work to globalise the SLIT-tablet portfolio.”
In his previous role as Head of Respiratory at Merck Sharp & Dome, Hendrik Nolte led the development and registration efforts for ALK’s grass and ragweed SLIT-tablets – GRASTEK® and RAGWITEK® – as well as for the house dust mite SLIT-tablet.
Hendrik Nolte commented: "I am honoured to have the opportunity to return to ALK. Throughout my career, as both a physician and a scientist, I have been impressed by ALK’s commitment to cure allergies. Allergy research and respiratory medicine has been my life’s work and I am continually motivated by both the unmet medical need of patients, particularly those with respiratory allergies, and by the growing scientific evidence in favour of treatment with allergy immunotherapy."
Hendrik Nolte has held roles in clinical research at Roche, Hycor Biomedical and ALK. Before assuming leadership roles at Merck in 2005, Hendrik Nolte was an associate professor at the Department of Internal Medicine at the University of Copenhagen, where he also served as a lung specialist and head of the respiratory ward at Bispebjerg University Hospital. Hendrik Nolte received his medical degree (M.D) from University of Copenhagen in 1985 and received his doctoral degree (Dr. Med) in 1992.
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.